- Home
- / Spark Therapeutics
Spark Therapeutics
Stock Price
$113.6
2019-12-17
Market Capitalization
$4.4 B
2019-12-17
Revenue
$64.7 M
FY, 2018
Spark Therapeutics Summary
Company Summary
- Overview
- Spark Therapeutics is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Philadelphia, PA, US | view all locations
- Website
- http://sparktx.com
- Cybersecurity rating
Table of Contents
Key People
Lars Ekman, Director
Katherine A. High, President and Head of Research and Development
Stephen Webster, Chief Financial Officer
Operating MetricsView all
Patents and Patent Applications
297
FY, 2016
LocationsView all
1 location detected
Philadelphia, PA HQ
United States
3737 Market St
Spark Therapeutics Financials
Summary Financials
- Revenue (Q3, 2019)
- $22.4M
- Net income (Q3, 2019)
- ($66.6M)
- Cash (Q3, 2019)
- $207.1M
- EBIT (Q3, 2019)
- ($68.7M)
- Enterprise value
- $4.2B